Clinical trials

Ongoing Protocols : click on the protocol for the inclusion-exclusioncriteria (update 08/01/2018)

NON-SMALL CELL LUNG CANCER

Locally advanced

PET Boost
Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC.

PEARLS (MSD)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy.

Advanced

LDK378-NIVOLUMAB (Novartis)
A multi-center, open-label study to assess the safety and efficacy of combination ceritinib (LDK378) and nivolumab in adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. 

INC280 (Capmatinib) (Novartis)
Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

ABEMACICLIB – PEMBROLIZUMAB (Lilly)
A Phase 2 Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV
Non-Small Cell Lung Cancer.

LXH254, LTT462 (Novartis)
A Phase Ib, open-label, multicenter study of oral LXH254 in combination with oral LTT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer. Temporarily on hold

CPDR001C2101 (Novartis)
Phase Ib, multicenter, open label study of PDR001 in combination with platinum-doublet chemotherapy in PD-L1 unselected, metastatic NSCLC patients.

BFAST (ROCHE)
A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cance (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial).

CHECKMATE 9LA (BMS)
A Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC).

SMALL CELL LUNG CANCER

Hippocampus Avoidance PCI vs PCI
Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in SCLC a Randomized Phase III Trial.

STIMULI (ETOP)
A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy.

TAHOE M16-289 (ABBVIE)
A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Comparedwith Topotecan for Subjects with Advanced or Metastatic DLL3high Small-cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Platinum-based Chemotherapy.

MESOTHELIOMA


OTHERS

For further information regarding protocols or clinical trial unit description, please contact the datamanagers:

christel.oyen@uzleuven.be
liesbet.peeters@uzleuven.be
stefanie.lepers@uzleuven.be                                                                                                                      raf.blomme@uzleuven.be